News

#CMSC16 – Novel Model of Home Care for Patients with Progressive MS Proven Beneficial, Increased Patients’ Satisfaction

A new model of care implemented to address the needs of patients with progressive multiple sclerosis (MS) and their caregivers has proven beneficial by reducing hospital stays, avoiding major care expenses, and improving patients’ satisfaction. The model has been tested in MS patients with high disability scores, and preliminary results of…

#CMSC16 – Interview with Bayer’s VP and General Manager on Betaconnect/Betaseron and Customized Therapy

Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. In 1993, Bayer’s Betaseron (interferon beta-1b) became the first disease-modifying drug to be approved by the U.S. Food and Drug Administration (FDA) for…

#CMSC16 – Home Evaluation Prototype to Improve At-home Rehabilitation After Hospitalization

Researchers at the Shepherd Center in Atlanta are developing a prototype that addresses physical and cognitive parameters, daily routines, and homes of patients to better implement rehabilitation within the home environment. The study was presented in “Functional Home Evaluation: Missing Pieces in Treatment and Transition Processes” during the Consortium…

#CMSC16 – Study of PPMS Patient Characteristics Highlights Need for More Information

People with primary progressive multiple sclerosis (PPMS) are usually older and more disabled than those with relapsing-remitting MS, researchers at Washington University reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in the NARCOMS registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, “…

#CMSC16 – Treadmill Walking Improves Cognitive Processing in MS Patients

Treadmill walking exercise training is beneficial for multiple sclerosis (MS) patients, increasing not only their cardiorespiratory fitness, but also their cognitive processing speed, according to the study “Systematically Developed Pilot Randomized Controlled Trial of Exercise and Cognition in Persons with Multiple Sclerosis,” recently presented at the Consortium of Multiple…

#CMSC16 – Robot-assisted Rehabilitation May Improve MS Patient Locomotor Function

Robot-assisted training may be an effective therapy to improve motor function in the lower limbs of patients with multiple sclerosis (MS), and help in rehabilitation, according to the study “Robot-Guided Rehabilitation Improves Sensorimotor Functions in Lower-Limb Impairments of Individuals with Multiple Sclerosis,” presented at the Consortium of Multiple Sclerosis Centers…

#CMSC16 – Medical Affairs VP at EMD Serono Discusses MS Drug Rebif, MS LifeLines Support in Exclusive Interview

EMD Serono, the U.S. and Canadian subsidiary and biopharmaceutical business of Merck KGaA, focuses exclusively on specialty care. With expertise in fertility, endocrinology, oncology and neurology, the company is featuring several innovative products with therapeutic potential in the oncology, immuno-oncology, and immunology fields. Rebif (interferon beta-1a), EMD Serono’s therapy for patients with relapsing…

#CMSC16 – Lifestyle Factors and Unconventional Medicine in MS Care

A symposium focused on lifestyle factors and unconventional medicine as part of the clinical care provided to patients with multiple sclerosis (MS) took place today at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The symposium, “Expanding the MS Toolkit: Integrating Lifestyle Factors and Unconventional Medicine…

#CMSC16 – Patricia Coyle, an MS Expert, Talks About Vitamin D, Fatigue and Other Key Issues

The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting began today, June 1. Multiple Sclerosis News Today is providing extensive on-site coverage of the meeting, reporting on presentations, and conducting exclusive interviews with top researchers in the field of multiple sclerosis (MS) and with biopharmaceutical representatives on the latest advances in MS therapies.

MS Research Australia Supporting Effort to Harness Anti-inflammatory Potential of Parasitic Worms

Researchers at the University of Technology Sydney (UTS) ithree institute are taking a novel approach in an attempt to halt disease progression in multiple sclerosis (MS). The scientists are planning to explore the anti-inflammatory potential of a controlled infection by parasitic worms as a way of preventing the harmful over-inflammation observed in MS and…

MedDay Presents Phase 3 Extension Data on Potential Drug to Treat Progressive MS

Data from an extension phase of a Phase 3 clinical trial, given in an oral presentation by MedDay, reported that the biotin  MD1003 showed effectiveness over time as a possible treatment of non-active, progressive multiple sclerosis (MS). The data were presented at the recent 2nd Congress of the European Academy of Neurology (EAN) in Denmark by Professor Ayman Tourbah,…

Report Highlights Series of Changes Needed from Canadian Employers and Government to Improve MS Patients’ Lives

A new report by the Conference Board of Canada’s Canadian Alliance for Sustainable Health Care (CASHC) notes that employers and the Canadian government are not giving enough support towards increasing workforce participation among patients with multiple sclerosis (MS), despite the clear benefits such support would mean to not only the well-being of individuals…

Mitochon Raises $1.6M to Begin Clinical Tests of Mitochondrial Modulators for MS

Mitochon Pharmaceuticals announced the completion of a second year of financing, raising a total $1.6 million to advance its lead compound, MP101, a mitochondrial targeted neuro-protective agent, into clinical testing. The company is developing mitochondrial modulators for patients with neurodegenerative diseases ranging from Alzheimer’s and Parkinson’s to multiple sclerosis (MS). A number of studies have…